Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel R Chamberlain

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2007
Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfectaJoel R Chamberlain, David R Deyle, Ulrike Schwarze, et al.
Molecular Therapy. Methods & Clinical Development|January 13, 2015
Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cellsAndrea Lh Arnett, Patryk Konieczny, Julian N Ramos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2011
AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophySergia Bortolanza, Alessandro Nonis, Francesca Sanvito, et al.
Nature Communications|February 15, 2017
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophyNiclas E Bengtsson, John K Hall, Guy L Odom, et al.
Nature Communications|June 24, 2017
Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophyNiclas E Bengtsson, John K Hall, Guy L Odom, et al.
Progress in Molecular Biology and Translational Science|December 6, 2011
Animal models of muscular dystrophyRainer Ng, Glen B Banks, John K Hall, et al.
Science (New York, N.Y.)|February 21, 2004
Gene targeting in stem cells from individuals with osteogenesis imperfectaJoel R Chamberlain, Ulrike Schwarze, Pei-Rong Wang, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2007
Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfectaJoel R Chamberlain, David R Deyle, Ulrike Schwarze, et al.
Molecular Therapy. Methods & Clinical Development|January 13, 2015
Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cellsAndrea Lh Arnett, Patryk Konieczny, Julian N Ramos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2011
AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophySergia Bortolanza, Alessandro Nonis, Francesca Sanvito, et al.
Nature Communications|February 15, 2017
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophyNiclas E Bengtsson, John K Hall, Guy L Odom, et al.
Nature Communications|June 24, 2017
Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophyNiclas E Bengtsson, John K Hall, Guy L Odom, et al.
Progress in Molecular Biology and Translational Science|December 6, 2011
Animal models of muscular dystrophyRainer Ng, Glen B Banks, John K Hall, et al.
Science (New York, N.Y.)|February 21, 2004
Gene targeting in stem cells from individuals with osteogenesis imperfectaJoel R Chamberlain, Ulrike Schwarze, Pei-Rong Wang, et al.
Pageof 2